BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: BMS-986165
Other: Placebo
Drug: Apremilast

First Posted Date: 2018-08-02

Last Posted Date: 2022-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1020

Registration Number: NCT03611751

Locations: 🇺🇸
Interspond - Savin Medical Group, Miami Lakes, Florida, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 195 locations

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Phase 2

Terminated

Conditions: Granulomatous Colitis
Crohn's Enteritis
Crohn's Disease
Granulomatous Enteritis

Interventions: Drug: BMS-986165
Other: Placebo

First Posted Date: 2018-07-26

Last Posted Date: 2024-07-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 239

Registration Number: NCT03599622

Locations: 🇺🇸
Local Institution - 0319, Chicago, Illinois, United States
🇺🇸
Local Institution - 0232, Miami, Florida, United States
🇺🇸
Local Institution - 0011, Las Vegas, Nevada, United States

and more 254 locations

The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung

Completed

Conditions: Pulmonary Thromboembolism
Pulmonary Embolism (PE)

Interventions: Other: Non-Interventional

First Posted Date: 2018-07-23

Last Posted Date: 2022-05-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 660

Registration Number: NCT03595891

Locations: 🇬🇧
Local Institution, Cardiff, United Kingdom

Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants

Completed

Conditions: Kidney Cancer
Renal Cancer

Interventions: Other: Non-Interventional

First Posted Date: 2018-06-26

Last Posted Date: 2022-10-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 212

Registration Number: NCT03568435

Locations: 🇯🇵
Local Institution - 0001, Tokyo, Japan

Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread

Completed

Conditions: Cancer of the Head
Cancer of the Neck
Cancer of Head and Neck

First Posted Date: 2018-06-26

Last Posted Date: 2022-02-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 262

Registration Number: NCT03569436

Locations: 🇯🇵
Local Institution, Tokyo, Japan

Study of the Sudden Heart Failure Participant Population in the US

Withdrawn

Conditions: Heart Decompensation

Interventions: Other: Non-Interventional

First Posted Date: 2018-06-25

Last Posted Date: 2022-07-08

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03566264

Locations: 🇺🇸
Bristol-Myers Squibb, Princeton, New Jersey, United States
🇺🇸
Local Institution, Princeton, New Jersey, United States

An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Rifampin
Drug: BMS-986224

First Posted Date: 2018-06-20

Last Posted Date: 2018-08-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 42

Registration Number: NCT03563950

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus
Healthy Participants

Interventions: Drug: BMS-986165
Other: Placebo
Drug: Moxifloxacin

First Posted Date: 2018-05-30

Last Posted Date: 2020-01-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT03541564

Locations: 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Completed

Conditions: Venous Thromboembolism (VTE)

First Posted Date: 2018-05-11

Last Posted Date: 2022-02-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35756

Registration Number: NCT03521908

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Phase 2

Terminated

Conditions: Urinary Bladder Neoplasms

Interventions: Biological: Nivolumab
Biological: BCG
Drug: BMS-986205

First Posted Date: 2018-05-08

Last Posted Date: 2023-06-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 142

Registration Number: NCT03519256

Locations: 🇺🇸
Local Institution - 0001, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0044, Los Angeles, California, United States
🇺🇸
Local Institution - 0140, Houston, Texas, United States

and more 81 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy